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Dear editor, 
We report on a case of psoriatic arthritis associ-
ated with nail psoriasis that was successfully treated 
with adalimumab. A 51-year-old Japanese woman 
presented with joint swelling and pain. She had no-
ticed fingernail deformity five years previously. Swell-
ing and pain of the 2nd and 4th distal interphalangeal 
(DIP) joints of the left hand had occurred about one 
year earlier, and had worsened three months before 
she attended our hospital for assessment. On exami-
nation, there was swelling and tenderness of the DIP 
joints of both hands. There were multiple hyperkera-
totic punctate depressions on the nail plates of both 
hands, as well as scales and onycholysis with short-
ening of the nails (Figure 1), but her trunk and limbs 
showed no changes specific to psoriasis. Laboratory 
tests revealed elevation of C-reactive protein (CRP) to 
1.13 mg/dl and erythrocyte sedimentation rate to 38 
mm/h. However, rheumatic antibodies were negative, 
including antinuclear antibodies, rheumatoid factor, 
and anti-cyclic citrullinated peptide antibodies. Her 
human leukocyte antigen (HLA) status was A2, A26, 
B39, and B61. A plain X-ray film of the fingers revealed 
erosion and narrowing of the DIP joints of both hands. 
A diagnosis of psoriatic arthritis (PsA) associated with 
nail psoriasis was made from these joint and nail find-
ings. Oral methotrexate (MTX) was started at 4 mg/
week (maximum dose: 10 mg/week) for her arthritis. 
Although her joint symptoms improved temporally, 
nail symptoms did not. CRP also decreased, but it in-
creased again after 16 months. Recurrent synovitis 
was diagnosed and treatment with adalimumab (40 
mg biweekly) was started. CRP improved rapidly, and 
her nail lesions resolved completely after five months 
of adalimumab therapy (Figure 2). Currently, inflam-
mation is suppressed and her nail deformity has not 
recurred.
PsA has been reported to affect from 5% to 42% of 
patients with psoriasis (1,2). Involvement of the nails 
is more frequent in patients with PsA than in those 
without PsA, and nail lesions with or without other 
skin lesions have been observed in about 80% of 
patients with PsA (8). However, there has only been 
Figure 1. Magnified nail findings at initial examina-
tion: Multiple hyperkeratotic punctate depressions, 
onycholysis, shortened nails, and swelling of the DIP 
joints of the 3rd and 5th fingers.
Figure 2. Nail findings 5 months after treatment with 
adalimumab: All lesions on the nail plates have disap-
peared.
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one previous report of PsA with psoriatic eruptions 
localized to the nails, as in our case (3). It has been 
reported that PsA is related to specific HLA types. 
While ankylosing spondylitis has a strong relation 
with HLA-27, it has been reported that HLA-B13, B17 
(including the subtypes B38 and B39), Cw6, Cw7, DR4, 
and DR7 are relevant to PsA (4,5). In addition, relation 
of PsA with HLA-A2 has been reported in Japanese 
patients (6,7). Our patient had an increase in both 
HLA-A2 and B39. Recently, it has become evident that 
PsA often has a chronic progressive course with early 
bone destruction, and causes marked impairment of 
the quality of life (6,7). A randomized double-blind 
trial of methotrexate (MTX) demonstrated it to be 
an efficient treatment only for arthritis in patients 
with psoriasis (8). In our patient, PsA was temporar-
ily improved by MTX, but her punctate nail depres-
sions and onycholysis did not resolve. Therefore, we 
switched to adalimumab to treat both PsA and nail 
lesions. Adalimumab was not only shown to improve 
skin eruptions but also improved joint symptoms and 
inhibited the progression of joint destruction in a pla-
cebo-controlled double-blind trial (9). Tumor necrosis 
factor inhibitors have only been used to treat PsA for 
a few years. Treatment with these drugs must be per-
formed effectively and safely.
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